These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36212476)

  • 1. LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer.
    Song Z; Wang X; Chen F; Chen Q; Liu W; Yang X; Zhu X; Liu X; Wang P
    Front Oncol; 2022; 12():1004212. PubMed ID: 36212476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
    Zhao C; Ling X; Xia Y; Yan B; Guan Q
    Cancer Cell Int; 2021 Aug; 21(1):441. PubMed ID: 34419065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
    Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
    Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
    Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
    Front Immunol; 2022; 13():976107. PubMed ID: 36091006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. METTL3-modified lncRNA-MALAT1 regulates the molecular axis of miR-124-3p/CDK4 involved in Ewing's sarcoma.
    He F; Ren T; Tang X
    Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):193-197. PubMed ID: 37605570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. METTL3-Mediated m
    Mao Y; Li W; Weng Y; Hua B; Gu X; Lu C; Xu B; Xu H; Wang Z
    Cell Transplant; 2022; 31():9636897221122997. PubMed ID: 36073002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
    Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
    Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer.
    Xu Z; Chen Q; Shu L; Zhang C; Liu W; Wang P
    Front Oncol; 2022; 12():970367. PubMed ID: 36003776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
    Liu X; Ma C; Liu H; Sun Z; Luo J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma.
    Chang YZ; Chai RC; Pang B; Chang X; An SY; Zhang KN; Jiang T; Wang YZ
    Cancer Lett; 2021 Jul; 511():36-46. PubMed ID: 33933553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S; Wang K; Huang X; Zhao Z; Zhao Z
    Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer.
    Li S; Jiang F; Chen F; Deng Y; Pan X
    J Biochem Mol Toxicol; 2022 Jan; 36(1):e22922. PubMed ID: 34964205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM; Lian GY; Song Y; Huang YF; Gong Y
    Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy.
    Yu H; Liu J; Bu X; Ma Z; Yao Y; Li J; Zhang T; Song W; Xiao X; Sun Y; Xiong W; Shi J; Dai P; Xiang B; Duan H; Yan X; Wu F; Zhang WC; Lin D; Hu H; Zhang H; Slack FJ; He HH; Freeman GJ; Wei W; Zhang J
    Cell Chem Biol; 2024 Apr; 31(4):776-791.e7. PubMed ID: 37751743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
    Ai Y; Liu S; Luo H; Wu S; Wei H; Tang Z; Li X; Lv X; Zou C
    J Immunol Res; 2021; 2021():6149558. PubMed ID: 34476262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Analysis of the Immune Infiltrates and PD-L1 Expression of N6-Methyladenosine-Related Long Non-Coding RNAs in Colorectal Cancer.
    Jiang Z; Zhang Y; Chen K; Yang X; Liu J
    Int J Gen Med; 2021; 14():5017-5028. PubMed ID: 34511985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative Analyses of m6A Regulators Identify that METTL3 is Associated with HPV Status and Immunosuppressive Microenvironment in HPV-related Cancers.
    Yu R; Wei Y; He C; Zhou P; Yang H; Deng C; Liu R; Wu P; Gao Q; Cao C
    Int J Biol Sci; 2022; 18(9):3874-3887. PubMed ID: 35813476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer.
    Pang EJ; Yang R; Fu XB; Liu YF
    Tumour Biol; 2015 Apr; 36(4):2403-7. PubMed ID: 25481511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors.
    Iaiza A; Tito C; Ianniello Z; Ganci F; Laquintana V; Gallo E; Sacconi A; Masciarelli S; De Angelis L; Aversa S; Diso D; Anile M; Petrozza V; Facciolo F; Melis E; Pescarmona E; Venuta F; Marino M; Blandino G; Fontemaggi G; Fatica A; Fazi F
    Clin Epigenetics; 2021 Sep; 13(1):173. PubMed ID: 34530916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.